• Researcher Profile

    Kwok-Kin Wong, MD, PhD

    Scientific Director, Belfer Institute for Applied Cancer Science

    Professor of Medicine, Harvard Medical School


    Thoracic Oncology

    Office phone: 617-632-6084
    Fax: 617-582-7683
    Website: Wong Lab Website

    Preferred contact method: office phone

    View Physician Profile


    Lung cancer, Developmental therapeutics

    Area of Research

    Pathogenesis of Human Lung Cancer

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Boston, MA 02215

    Recent Awards

    • Team Science Award AACR, 2010
    • Tisch Family Outstanding Award in Translational Research, 2008
    • Sidney Kimmel Foundation Scholar, 2004
    • Tisch Foundation Solid Tumor Scholar Award, 2004


    Pathogenesis of Human Lung Cancer

     As a basic/translational physician scientist, I focus on advancing our understanding of the pathogenesis and genetic alterations involved in lung tumorigenesis and testing novel lung cancer therapeutics in vivo, with the goal of developing approaches to improve outcomes for lung cancer patients.  

    My lab has experience using novel approaches to advance our understanding of lung cancer pathogenesis and uncover potential treatment modalities. Major scientific achievements with important clinical implications have been focused in 3 areas: (1) discovering novel genetic alterations in human lung cancer that are important in lung cancer initiation, progression and acquired resistance to initially effective novel therapeutics, (2) generating and characterizing genetically engineered mouse models based on novel lung-relevant human genetic alterations to genetically validate the importance of these mutations and for preclinical testing of targeted therapeutics, and (3) pioneering the paradigm of using these mouse models in clinical trials in mice and humans in parallel, to guide future targeted human clinical trials.  

    My work using genetically engineered mouse lung cancer models to validate oncogenic drivers and test novel therapeutics against specific genetic oncogenic drivers has been acknowledged by the international cancer scientific community as a novel means for credentialing new genetic alterations, and has changed the way innovative therapeutics are tested preclinically. This new paradigm has changed cancer drug development and facilitated design of rationally and genetically stratified human cancer clinical trials. Several global pharmaceutical companies and academic centers have adopted the murine co-clinical trial paradigm for drug development.  

    The DFCI Belfer Center focus is on novel cancer target discovery/validation and novel drug development, with 50 personnel. As Director, I have integrated academic, industry and clinical resources/expertise to enhance success in scientifically informed oncology drug discovery. The Institute’s excellence in early-stage biology, with Belfer scientists who have industry experience collaborating with DFCI clinical and academic investigators, enables our scientists to define the best targets and delineate the optimal clinical path for targeted cancer therapies, with the potential for accelerating cancer care approaches.

    In summary, my laboratory, clinical care, mentorship, and Belfer Center leadership have enabled me to build an influential investigative and clinical approach, with major scientific discoveries that have been internationally recognized for the rapid development and application of novel strategies to research and management of lung and other cancers. I use this constellation of tools to make a meaningful impact on lung cancer outcomes.


    • Hongbin, Ji, PhD
    • Perera, Samanthi, PhD
    • Shimamura, Takeshi, PhD
    • Liang, Chen, PhD
    • Liang, Mei-Chih (Amy), PhD
    • Tan, Xiao Hong (Joy), PhD
    • Gandhi, Leena, MD, PhD
    • Carretero, Julian, PhD
    • Xu, Chunxiao, PhD
View Physician Directory

Find a Clinical Trial

Support Cancer

Give Now